Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inotuzumab ozogamicin + rituximab versus investigator's choice therapy in relapsed or refractory CD22-positive follicular lymphoma
2007-000219-27Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of inotuzumab ozogamicin and rituximab in follicular lymphoma (FL) and non-Hodgkin lymphoma (NHL) (2 arms), sponsored by Pfizer. Primary endpoints: Progression-free survival and Safety and tolerability. Started Jan 2008; status: completed.
02
Drugs
inotuzumab ozogamicinrituximab
03
Conditions
follicular lymphoma (FL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2007-000219-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000219-27.